WBCIL Makes History as India’s Sole MSME Honored with National Intellectual Property Award 2024

Pioneering Patent Excellence and Global Innovation from Bengal to the World

(industrietreff) - New Delhi, March 26, 2025 – In a landmark achievement that spotlights India's innovation prowess on the global stage, West Bengal Chemical Industries Limited (WBCIL) has been crowned the only MSME in India to receive the prestigious National Intellectual Property (IP) Award 2024, awarded by the Ministry of Commerce & Industry, Government of India.

The recognition was conferred under the coveted category of “Top Indian MSME for Patent Filing, Grant & Commercialization,” during a grand ceremony held at Bharat Mandapam, Pragati Maidan, New Delhi. The event was graced by Hon’ble Minister Shri Piyush Goyal, Hon’ble Justice Pratibha M. Singh of the Delhi High Court, and a distinguished gathering of policymakers, inventors, entrepreneurs, and industry leaders.

---

A National Milestone, A Global Message

While presenting the awards, Shri Piyush Goyal reinforced the government’s dedication to innovation-driven progress, stating, “Innovation is the key to India's march towards a Viksit Bharat.” The statement resonates with the spirit of WBCIL, whose sustained commitment to science-backed invention, intellectual property, and global regulatory compliance has set a new benchmark for Indian MSMEs.

The National Intellectual Property Awards, organized annually by the Department for Promotion of Industry and Internal Trade (DPIIT) in collaboration with the Indian IP Office, are among the highest honors in the country. These awards recognize organizations and individuals that make outstanding contributions to the development and commercialization of IP assets — a crucial pillar in India’s ambition to become a global innovation leader.

---

WBCIL’s Innovation Footprint: 60+ Years of Scientific Leadership

Since its founding in 1962, West Bengal Chemical Industries Limited (WBCIL) has steadily evolved from a trusted manufacturer of fine APIs into a pioneering force in the field of life sciences. What began as a modest operation rooted in chemical synthesis has blossomed into a globally recognized, innovation-driven company delivering impactful solutions in the fields of Active Pharmaceutical Ingredients (APIs), nutraceuticals, mineral salts, and liposomal delivery technologies.

At the heart of WBCIL’s journey is a strong R&D-first philosophy. This commitment to continuous innovation and scientific exploration has not only set the company apart but has allowed it to lead the way in preventive and personalized healthcare — a domain increasingly valued in today’s wellness-conscious world. By investing in cutting-edge research, modernizing its manufacturing processes, and cultivating a team of experienced

scientists and formulation experts, WBCIL has built a robust legacy rooted in credibility, quality, and global relevance.

Today, WBCIL stands proud with a growing intellectual property (IP) portfolio, comprising 15 patents filed and 9 successfully granted across various jurisdictions. What makes this even more remarkable is that a majority of these innovations have moved beyond paper, progressing into commercialized formulations that are making tangible differences in patient care both in India and international markets.

These patents cover a diverse range of next-generation active ingredients, including:

· Ferric Carboxymaltose – a clinically relevant injectable iron formulation known for better tolerability and sustained release.

· Iron Isomaltoside – providing rapid correction of iron deficiency anemia with minimal side effects.

· Iron (III) Coordination Complex – designed for enhanced stability and reduced gastrointestinal discomfort.

· Ferric Derisomaltose – used particularly in chronic kidney disease (CKD) and supportive therapy.

· Ferric Citrate – a dual-acting compound effective in phosphate control and iron supplementation.

· Sucroferric Oxyhydroxide – an advanced phosphate binder with better palatability and patient compliance.

· Enclomiphene Citrate – a novel fertility support molecule for male hypogonadism and hormone modulation.

· Ferric Maltol (novel polymorphic forms – Form S) – a patent covering a unique, more stable and bioavailable version of ferric maltol.

· Improved Ferric Carboxymaltose – an upgraded, cost-effective process design that enhances safety and reduces side effects, making it ideal for scalable global deployment.

What unites these diverse formulations is their real-world applicability. Each product targets pressing health concerns like iron-deficiency anemia, chronic disease management, fertility enhancement, and metabolic dysfunction — conditions that are rising globally, particularly in emerging economies like India.

By prioritizing bioavailability, safety, patient compliance, and cost-efficiency, WBCIL has positioned itself not just as a contract manufacturer or supplier, but as a solutions provider. This distinguishes the company in a crowded API market where true innovation — especially within the MSME sector — is still rare.

In particular, WBCIL’s pioneering work in liposomal delivery technology has opened new doors for the future of nutraceuticals and cosmeceuticals. By combining mineral science with phospholipid-based encapsulation systems, WBCIL is advancing the science of ingredient absorption, setting new standards in gut-friendly, high-potency formulations.

As the company continues to innovate, it maintains a deep focus on quality control, regulatory compliance, and international documentation, ensuring that its products are not only effective but also globally acceptable.

In every patent, every formulation, and every process innovation, WBCIL demonstrates a visionary blend of tradition and modernity, of Indian scientific legacy and global business acumen — creating healthcare that is smarter, safer, and more sustainable.


Liposomal APIs: WBCIL’s Future-Ready Advantage

One of the company’s standout differentiators is its pioneering work in liposomal API delivery systems — an area increasingly recognized for enhancing bioavailability, targeted delivery, and gut tolerance in supplements and pharmaceuticals.

WBCIL’s liposomal line now includes Liposomal Vitamin C, Liposomal Glutathione, Liposomal Magnesium, Liposomal Zinc, and cosmeceutical-grade liposomal actives like Niacinamide, Hyaluronic Acid, and Alpha Lipoic Acid — all developed to meet global trends in functional health and beauty from within.

---

WHO-GMP Certification: Another Global Stamp of Trust

In addition to its IP triumph, WBCIL has also secured WHO-GMP certification, reinforcing its credibility as a manufacturer that adheres to international pharmaceutical quality and safety standards. As part of this achievement, WBCIL has received Certificates of Pharmaceutical Product (COPP) for several critical APIs, including:

· Ferric Ammonium Citrate B.P

· Calcium Acetate USP

· Calcium Citrate USP

· Ferrous Bisglycinate (In-House Spec)

These approvals open new doors for exports to regulated markets and affirm the company's dedication to global compliance and trust-based partnerships.

---

The Man Behind the Mission: Mr. Sunil Kumar Agarwal

Speaking on this prestigious recognition, Mr. Sunil Kumar Agarwal, Managing Director of WBCIL, said:

“This award is more than a medal—it’s a recognition of every sleepless night spent innovating, every formulation perfected, and every challenge turned into opportunity. We are proud to represent the MSME sector on a national platform and prove that Indian enterprises can compete — and lead — globally through innovation and excellence.”

Mr. Agarwal’s visionary leadership has transformed WBCIL from a regional manufacturer into a globally recognized name in science-led, IP-rich, and patient-centric formulations.

---

Why This Award Matters — For India and for MSMEs

WBCIL’s recognition sends a powerful message: that size is no barrier to innovation. As the only MSME across India to win this prestigious award, the company represents the growing intellectual capital and R&D strength within India’s micro, small, and medium enterprise ecosystem.

In a landscape where many MSMEs struggle with R&D funding, global competition, and IP protection, WBCIL has become a national case study on how innovation, strategy, and vision can align to create transformative impact.

---

Looking Ahead: Science, Scale, and Global Impact

With innovation embedded in its DNA, WBCIL is now expanding into:

· Custom B2B ingredient solutions for pharma, nutra, and cosmeceutical clients

· Formulation-ready APIs for advanced delivery systems (liposomes, granules, injectables)

· Partnerships with global health and wellness brands looking for high-purity, IP-backed ingredients

Its growth strategy is focused not just on formulating products, but on formulating better health outcomes, globally.

---
???? Visit: https://www.wbcil.com/

Themen in dieser Meldung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
Kontakt / Agentur:
Bereitgestellt von Benutzer: WBCIL
Datum: 07.05.2025 - 09:14 Uhr
Sprache: Deutsch
News-ID 2170022
Anzahl Zeichen: 0

Kontakt-Informationen:
Ansprechpartner:
Stadt:

Kolkata

Telefon:

Kategorie:

Chemische Industrie

Anmerkungen:


Diese HerstellerNews wurde bisher 0 mal aufgerufen.


Die Meldung mit dem Titel:
"WBCIL Makes History as India’s Sole MSME Honored with National Intellectual Property Award 2024
"
steht unter der journalistisch-redaktionellen Verantwortung von

West Bengal Chemical Industries Ltd (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von West Bengal Chemical Industries Ltd

• IVA: Zulassungssystem verbessern, Klimaschutz-Investitionen sichern / Wirtschaftsverband setzt auf zügige Umsetzung der Agrar-Themen des Koalitionsvertrags / Pflanzenschutz- und Düngermarkt schwach

• WD-40® Company Limited fährt vorne mit – starke Partnerschaft mit A.S.O. Germany GmbH zur Förderung des Radsports

• Maximale Power – Elektrogießharze von RAMPF

• Neu von RAMPF: Elektrovergusssysteme für den Schienenverkehr